生物膜療法市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、傷口類型、最終用戶、地區和競爭對手分類，2021-2031年

全球生物膜處理市場預計將從 2025 年的 18.2 億美元成長到 2031 年的 25.2 億美元，複合年成長率為 5.57%。

該市場涵蓋專門的抗菌劑、酵素分解劑和清創技術，旨在清除生物和醫療表面上的結構化微生物群落。其成長主要受慢性傷口（例如糖尿病潰瘍）發病率上升以及與留置醫療設備相關的醫院感染增加的推動。這些情況需要超越傳統抗生素的先進治療方案來解決持續存在的細菌定植問題。例如，英國國家生物膜創新中心報告稱，2024年，52家公司參與的65項合作舉措，旨在加速生物膜管理解決方案的研發，專案總價值達到540萬英鎊。

市場促進因素

全球生物膜治療市場的主要驅動力是日益嚴重的抗菌素抗藥性（AMR）威脅，這促使人們從傳統抗生素轉向先進的破壞性技術。生物膜內的細菌對標準治療方法的抗藥性日益增強，因此迫切需要酵素法和機械清除方法。世界衛生組織（WHO）發布的《2024年細菌病原體優先清單》（2024年5月）進一步強調了這項公共衛生挑戰，該清單列出了15個應優先研究的抗藥性細菌家族。同時，慢性感染疾病和生物膜相關感染疾病的日益普遍，尤其是在高級創傷護理領域，也顯著推動了市場擴張。糖尿病足潰瘍和靜脈性腿部潰瘍等慢性傷口通常會形成強大的微生物群落，阻礙癒合，因此需要使用專門的抗菌敷料和清創器械。這種日益成長的需求在醫療技術領域尤其明顯。例如，康維德集團（Convatec Group Plc）的先進創傷護理業務在2023年實現了9.5%的有機銷售成長，主要得益於抗菌療法的推動。史密斯醫療（Smith+Nephew）在其2023年年度報告中也指出，其集團總銷售額達到55.49億美元，凸顯了專注於外科手術和先進傷口護理的行業的龐大規模。

市場挑戰

市場商業性發展的主要障礙在於缺乏標準化的監管指南來檢驗抗生物膜功效聲明。目前，監管機構缺乏清晰統一的流程來核准明確標註「清除生物膜」的產品。這種監管上的模糊性迫使製造商將先進技術以一般創傷護理的名義進行銷售，從而阻礙了他們基於對抗藥性微生物的卓越療效來區分產品的能力。因此，企業在證明其高價策略的合理性方面面臨挑戰，而高價策略對於收回研發投資至關重要，這導致投資意願下降，並延緩了新療法的上市。這項監管空白極大地限制了市場解決大量臨床病例的潛力。例如，預計到2025年，將有約1,050萬聯邦醫療保險受益人受到慢性傷口的影響。儘管這些患者對專門的生物膜治療需求極高，但由於監管限制，他們無法使用檢驗的療效聲明來明確針對這些病例，阻礙了市場滲透。這直接阻礙了產生收入，由於將臨床需求與商業性可行性脫鉤，限制了全球市場的整體擴張。

市場趨勢

噬菌體療法作為抗生素的替代方案的出現，標誌著在應對生物膜抗藥性方面發生了重大模式轉移，從傳統的小分子抗菌劑轉向了精準的生物製藥。與抗生素通常難以穿透細胞外聚合物基質不同，噬菌體可以在生物膜內自我複製，高效靶向並裂解銅綠假單胞菌等抗藥性菌株。這種治療效果已得到充分的臨床證實，證明其具有解決對標準療法無效的性行為感染的潛力。例如，BiomX公司於2025年7月在《自然通訊》雜誌上發表報告稱，在慢性囊腫纖維化感染疾病患者中，霧化吸入噬菌體混合物「BX004」可使細菌數量減少約500倍（與安慰劑相比）。同時，整合人工智慧和生物感測器的即時生物膜檢測技術正在革新傷口管理，能夠在出現視覺症狀之前客觀地識別感染生物標記。先進的穿戴式技術如今結合了微流體感測器和機器學習演算法，能夠持續監測傷口微環境，使臨床醫生能夠在感染早期階段主動干預，而非被動應對已出現的併發症。這種預防性方法已被證明對改善複雜慢性傷口患者的預後至關重要。 2025年4月，加州理工學院在20名患者中檢驗了一種新型生物電子設備的有效性，證明其能夠在臨床症狀出現前1至3天檢測到一氧化氮和過氧化氫等關鍵感染指標。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球生物膜療法市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類別（清創器材、紗布/敷料、凝膠、軟膏/噴霧、植皮/基質、擦拭巾、墊片/清潔液）
  • 傷口類型（燒傷/開放性傷口、糖尿病足潰瘍、壓瘡、外傷/手術傷口、靜脈性小腿潰瘍）
  • 按最終使用者（居家照護、醫院、門診手術中心 (ASC) 和創傷護理中心）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美生物膜療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲生物膜療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區生物膜療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲生物膜療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲生物膜治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球生物膜療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Smith+Nephew healthcare private limited
• ConvaTec Group plc
• Zimmer Biomet Holdings, Inc.
• Molnlycke Healthcare AB
• Organogenesis Inc.
• Integra LifeSciences Holdings Corp
• B. Braun Melsungen AG
• PAUL HARTMANN AG
• Medline Industries Inc.
• Welcare Industries SpA

第16章 策略建議

第17章：關於研究公司及免責聲明

The global market for biofilm treatment is projected to expand from USD 1.82 billion in 2025 to USD 2.52 billion by 2031, demonstrating a 5.57% compound annual growth rate. This market includes specialized antimicrobial agents, enzymatic disruptors, and debridement technologies aimed at eliminating structured microbial communities found on biological and medical surfaces. Its growth is largely fueled by the increasing occurrence of chronic wounds, such as diabetic ulcers, and a rising number of healthcare-associated infections associated with indwelling medical devices. These conditions demand advanced therapeutic solutions that go beyond traditional antibiotics to tackle persistent bacterial colonization. Illustrating this commitment, the National Biofilms Innovation Centre reported a cumulative project value of £5.4 million in 2024, stemming from 65 collaborative initiatives involving 52 companies focused on accelerating biofilm management solutions.

Market Driver

The primary catalyst for the Global Biofilms Treatment Market is the escalating threat of antimicrobial resistance (AMR), which is compelling a shift from conventional antibiotics to advanced disruption technologies. Bacteria within biofilms display significantly increased tolerance to standard treatments, creating an urgent clinical need for enzymatic and mechanical eradication methods. This public health challenge was reinforced by global health authorities, with the World Health Organization's 'WHO Bacterial Priority Pathogens List 2024' (May 2024) identifying 15 families of antibiotic-resistant bacteria for priority research. Concurrently, the increasing prevalence of chronic and biofilm-associated infections, particularly in advanced wound care, significantly boosts market expansion. Chronic wounds like diabetic foot ulcers and venous leg ulcers are often colonized by robust microbial communities that impede healing, necessitating specialized antimicrobial dressings and debridement devices. This rising demand is evident in the medical technology sector; for example, Convatec Group Plc's Advanced Wound Care business achieved 9.5% organic revenue growth in 2023, largely driven by antimicrobial therapies, and Smith+Nephew reported total Group revenue of $5,549 million in its 2023 Annual Report, highlighting the substantial industrial scale dedicated to surgical and advanced wound management.

Market Challenge

A significant impediment to the market's commercial advancement is the absence of standardized regulatory guidelines for validating antibiofilm claims. Regulatory agencies currently lack a clear, unified process for approving products specifically labeled for biofilm eradication. This regulatory ambiguity compels manufacturers to market advanced technologies under general wound care indications, hindering their ability to differentiate products based on superior efficacy against resistant microbial communities. As a result, companies face challenges in justifying the premium pricing needed to recover research investments, leading to diminished investment confidence and a slower introduction of novel therapeutics. This regulatory gap severely limits the market's potential to address a large volume of clinical cases; for instance, approximately 10.5 million Medicare beneficiaries are projected to be affected by chronic wounds in 2025. Despite this substantial patient demand for specialized biofilm treatments, the regulatory inability to explicitly target these cases with validated claims constrains market penetration, directly impeding revenue generation and suppressing the global sector's overall expansion by separating clinical necessity from commercial execution.

Market Trends

The emergence of bacteriophage therapy as a non-antibiotic alternative marks a critical paradigm shift in tackling biofilm tolerance, moving beyond conventional small-molecule antimicrobials towards precision biological agents. Unlike antibiotics, which often struggle to penetrate the extracellular polymeric substance matrix, bacteriophages can self-replicate within the biofilm, efficiently targeting and lysing resistant bacterial strains such as Pseudomonas aeruginosa. This therapeutic efficacy is receiving substantial clinical validation, showcasing its potential to resolve persistent infections where standard treatments have proven ineffective. BiomX Inc., for instance, reported a roughly 500-fold bacterial reduction with its nebulized phage cocktail BX004 compared to placebo in patients with chronic cystic fibrosis infections, as detailed in their Phase 1b/2a trial results published in Nature Communications in July 2025. Simultaneously, the integration of AI and biosensors for real-time biofilm detection is revolutionizing wound management by facilitating the objective identification of infection biomarkers before visual symptoms appear. Advanced wearable technologies now combine microfluidic sensors with machine learning algorithms to continuously monitor the wound microenvironment, enabling clinicians to intervene proactively at the initial stages of colonization instead of responding to established complications. This proactive approach is proving vital for enhancing patient outcomes in complex chronic wounds, with the California Institute of Technology validating a new bioelectronic device across 20 human patients in April 2025, demonstrating its capacity to detect critical infection indicators like nitric oxide and hydrogen peroxide one to three days prior to clinical manifestation.

Key Market Players

• Smith+Nephew healthcare private limited
• ConvaTec Group plc
• Zimmer Biomet Holdings, Inc.
• Molnlycke Healthcare AB
• Organogenesis Inc.
• Integra LifeSciences Holdings Corp
• B. Braun Melsungen AG
• PAUL HARTMANN AG
• Medline Industries Inc.
• Welcare Industries S.p.A.

Report Scope

In this report, the Global Biofilms Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biofilms Treatment Market, By Product

• Debridement Equipment
• Gauzes & Dressings
• Gels
• Ointments & Sprays Grafts & Matrices
• Wipes
• Pads & Lavage Solutions

Biofilms Treatment Market, By Wound Type

• Burns & Open Wounds
• Diabetic Foot Ulcers
• Pressure Ulcers
• Traumatic & Surgical Wounds
• Venous Leg Ulcers

Biofilms Treatment Market, By End user

• Home Care Settings
• Hospitals
• ASCs & Wound Care Centers

Biofilms Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biofilms Treatment Market.

Available Customizations:

Global Biofilms Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biofilms Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Debridement Equipment, Gauzes & Dressings, Gels, Ointments & Sprays Grafts & Matrices, Wipes, Pads & Lavage Solutions)
  • 5.2.2. By Wound Type (Burns & Open Wounds, Diabetic Foot Ulcers, Pressure Ulcers, Traumatic & Surgical Wounds, Venous Leg Ulcers)
  • 5.2.3. By End user (Home Care Settings, Hospitals, ASCs & Wound Care Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Biofilms Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Wound Type
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biofilms Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Wound Type
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Biofilms Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Wound Type
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Biofilms Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Wound Type
      • 6.3.3.2.3. By End user

7. Europe Biofilms Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Wound Type
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Biofilms Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Wound Type
      • 7.3.1.2.3. By End user
  • 7.3.2. France Biofilms Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Wound Type
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Biofilms Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Wound Type
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Biofilms Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Wound Type
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Biofilms Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Wound Type
      • 7.3.5.2.3. By End user

8. Asia Pacific Biofilms Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Wound Type
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Biofilms Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Wound Type
      • 8.3.1.2.3. By End user
  • 8.3.2. India Biofilms Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Wound Type
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Biofilms Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Wound Type
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Biofilms Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Wound Type
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Biofilms Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Wound Type
      • 8.3.5.2.3. By End user

9. Middle East & Africa Biofilms Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Wound Type
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Biofilms Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Wound Type
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Biofilms Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Wound Type
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Biofilms Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Wound Type
      • 9.3.3.2.3. By End user

10. South America Biofilms Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Wound Type
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Biofilms Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Wound Type
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Biofilms Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Wound Type
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Biofilms Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Wound Type
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Biofilms Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Smith+Nephew healthcare private limited
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ConvaTec Group plc
• 15.3. Zimmer Biomet Holdings, Inc.
• 15.4. Molnlycke Healthcare AB
• 15.5. Organogenesis Inc.
• 15.6. Integra LifeSciences Holdings Corp
• 15.7. B. Braun Melsungen AG
• 15.8. PAUL HARTMANN AG
• 15.9. Medline Industries Inc.
• 15.10. Welcare Industries S.p.A.

16. Strategic Recommendations

17. About Us & Disclaimer